Atea Pharmaceuticals, Inc.
AVIR· Nasdaq
Released Nov 7, 2022, after the close
10-Q filed Nov 7, 2022, 38 days after period end · 0000950170-22-022699
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | — | $32.81M | — | — |
| Net Income | -$8.07M | -$28.19M | -$17.62M | -$3.63M |
| EPS Diluted |
Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR
| -$0.10 |
| -$0.34 |
| -$1.74 |
| -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.